Showing results (1-10 of 223) with videos related to

Sort By:
Pageof 23
Current Opinion in Oncology|April 9, 2014
Emerging new anticancer therapies in 2013Carlos Gomez-Roca, Jean-Pierre Delord
Investigational New Drugs|May 9, 2020
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trialBastien Cabarrou, Carlos Gomez-Roca, Marie Viala, et al.
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2018
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancerNicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, et al.
Melanoma Research|September 1, 2017
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combinationAmélie Aboudaram, Anouchka Modesto, Léonor Chaltiel, et al.
Investigational New Drugs|November 4, 2024
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trialMathilde Morisseau, Carlos Gomez-Roca, Marie Viala, et al.
Cancer Discovery|March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
Investigational New Drugs|November 10, 2018
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumorsElena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, et al.
Pageof 23